Nishadil
Signup Signin
Delhi | 25°C (windy)
The Unseen Hurdles: Intellia's Gene-Editing Dream Hits a Safety Snag

The Unseen Hurdles: Intellia's Gene-Editing Dream Hits a Safety Snag
Intellia Shakes Up Expectations: A Deep Dive into Their Q1 Surprise

Intellia Shakes Up Expectations: A Deep Dive into Their Q1 Surprise
A Sudden Chill for Intellia: FDA Hits Pause on Groundbreaking Gene Therapy Trial

A Sudden Chill for Intellia: FDA Hits Pause on Groundbreaking Gene Therapy Trial
Intellia's Big Chill: Manufacturing Woes Trigger a Wave of Downgrades

Intellia's Big Chill: Manufacturing Woes Trigger a Wave of Downgrades
A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World

A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World
The Shaking Ground: Intellia's Gene-Editing Dream Hits a Harsh Reality Check with Trial Setback

The Shaking Ground: Intellia's Gene-Editing Dream Hits a Harsh Reality Check with Trial Setback
The Great Market Paradox: Q3 2025 Sees Bears Roar on Headlines While Bulls & Gold Bugs Silently Reap Riches

The Great Market Paradox: Q3 2025 Sees Bears Roar on Headlines While Bulls & Gold Bugs Silently Reap Riches
Midday Market Movers: Biotech Rockets, Tech Soars, and a Coffee Giant Stumbles

Midday Market Movers: Biotech Rockets, Tech Soars, and a Coffee Giant Stumbles
Cathie Wood's ARK Invest Stacks Up on Alibaba, Baidu, and Biotech Gems in Active Week

Cathie Wood's ARK Invest Stacks Up on Alibaba, Baidu, and Biotech Gems in Active Week
Load more..